Literature DB >> 2498144

Persistent complement activation in submucosal blood vessels of active inflammatory bowel disease: immunohistochemical evidence.

T S Halstensen1, T E Mollnes, P Brandtzaeg.   

Abstract

Extensively washed and ethanol-fixed colonic specimens from 10 patients with ulcerative colitis, 3 patients with Crohn's disease of the colon, and 8 histologically normal controls were examined by two-color immunohistochemistry with monoclonal antibody to a neoepitope in the terminal complement complex combined with antiserum to factor VIII-related antigen (von Willebrand's factor), C3c, C3d, or C5. An alternative combination was monoclonal antibody to S-protein and antiserum to C9. Submucosal vessel walls in both normal and diseased colon showed parallel positivity for C3d, C5, C9, terminal complement complex, and S-protein, but the staining intensity and the proportion of positive vessels were significantly higher in inflammatory bowel disease than in controls. In addition, there was significantly more C3c reactivity associated with the terminal complement complex-positive submucosal vessels of active inflammatory bowel disease lesions than in histologically normal colon. Vascular C activation may therefore be a continuous process in active inflammatory bowel disease lesions, presumably related to the degree of inflammation and immune complex formation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2498144     DOI: 10.1016/0016-5085(89)91409-1

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  20 in total

1.  Cellular localization of complement C3 and C4 transcripts in intestinal specimens from patients with Crohn's disease.

Authors:  J Laufer; R Oren; I Goldberg; A Horwitz; J Kopolovic; Y Chowers; J H Passwell
Journal:  Clin Exp Immunol       Date:  2000-04       Impact factor: 4.330

2.  Surface epithelium related activation of complement differs in Crohn's disease and ulcerative colitis.

Authors:  T S Halstensen; T E Mollnes; P Garred; O Fausa; P Brandtzaeg
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

3.  Defective expression of gp180, a novel CD8 ligand on intestinal epithelial cells, in inflammatory bowel disease.

Authors:  L S Toy; X Y Yio; A Lin; S Honig; L Mayer
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

4.  Circulating von Willebrand factor in inflammatory bowel disease.

Authors:  T R Stevens; J P James; N J Simmonds; D A McCarthy; I F Laurenson; P J Maddison; D S Rampton
Journal:  Gut       Date:  1992-04       Impact factor: 23.059

5.  Counter-regulatory effect of sodium butyrate on tumour necrosis factor-alpha (TNF-alpha)-induced complement C3 and factor B biosynthesis in human intestinal epithelial cells.

Authors:  A Andoh; Y Fujiyama; K Hata; Y Araki; H Takaya; M Shimada; T Bamba
Journal:  Clin Exp Immunol       Date:  1999-10       Impact factor: 4.330

6.  Regulation of complement C3 synthesis by interleukin-1 and transforming growth factor-beta in rat non-transformed intestinal epithelial cell line, IEC-6.

Authors:  A Andoh; Y Fujiyama; K Hata; K Sumiyoshi; T Bamba
Journal:  J Gastroenterol       Date:  1996-10       Impact factor: 7.527

7.  Aetiology of Crohn's disease.

Authors:  T T MacDonald
Journal:  Arch Dis Child       Date:  1993-05       Impact factor: 3.791

8.  Location of tumour necrosis factor alpha by immunohistochemistry in chronic inflammatory bowel disease.

Authors:  S H Murch; C P Braegger; J A Walker-Smith; T T MacDonald
Journal:  Gut       Date:  1993-12       Impact factor: 23.059

9.  Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives.

Authors:  L Biancone; G Monteleone; R Marasco; F Pallone
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

10.  Local complement activation in inflammatory bowel disease.

Authors:  T S Halstensen; P Brandtzaeg
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.